Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNT2258 in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT01733238Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2012
- Primary completion
- Aug 2016
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Targeted Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of PNT2258 in non-Hodgkin lymphoma (NHL), sponsored by GSK. Started Nov 2012; status: completed.
02
Drugs
PNT2258
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01733238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01733238.